The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessment of PD-L1 expression and oncogenic gene status in patients with small-cell lung cancer: Immuno-oncology biomarker study in LC-SCRUM-Japan.
 
Satoshi Oizumi
Honoraria - AstraZeneca; Lilly
Research Funding - Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Pfizer (Inst)
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Kirin Pharmaceuticals; Lilly Japan; MSD; Novartis
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly Japan
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Shingo Matsumoto
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Pfizer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Riken Genesis (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Shingo Miyamoto
No Relationships to Disclose
 
Naoki Furuya
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim
 
Shinji Sasada
No Relationships to Disclose
 
Norio Okamoto
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; MSD; Ono Pharmaceutical
 
Yuichiro Hayashi
Employment - SRL Diagnostics
 
Koji Tsuta
Speakers' Bureau - MSD; Roche
 
Noriko Motoi
Honoraria - Agilent; AstraZeneca; Bristol-Myers Squibb Japan; MSD; Novartis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Miraca Life Sciences; MSD
Research Funding - Roche (Inst)
 
Genichiro Ishii
No Relationships to Disclose
 
Koichi Goto
Honoraria - AbbVie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Life Technologies; Lilly; Merck Serono; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Quintiles; RIKEN GENESIS; SRL Diagnostics; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Otsuka
Research Funding - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Janssen; Kyowa Hakko Kirin; Life Technologies; Lilly; Loxo; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Riken Genesis; RTI Health Solutions; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Xcoo